Delivery Order SPE2DB22D2214-SPE2DB25FS5EY
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,725.21 to AmerisourceBergen Drug Corp for HYSINGLA ER 20 mg tablets (60-count) on August 13, 2025, with completion scheduled for August 14, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026. The award was made on...
- The Defense Logistics Agency awarded a delivery order valued at $8,504.08 to AmerisourceBergen Drug Corp for the supply of Hysingla ER 20 mg tablets (60-count units) on September 5, 2025, with an ultimate completion date of September 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $2,843.74 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Hysingla ER 40 mg tablets (60-count). This contract represents a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 16, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed as a child contract...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,887.98 to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Hysingla ER 20 mg tablets (60-count packages). This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 31, 2025, with performance at the vendor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, for the supply of Hysingla ER 20 mg tablets (60-count packages) under a firm fixed-price contract valued at $1,066.00. The award, issued on August 29, 2025, with an ultimate completion date of September 2, 2025, represents a non-set-aside competitive procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- This federal contract award, valued at $2,434.36, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract for the supply of 4,568,177,973 units of the prescription medication HYSINGLA ER 20 MG TABLET 60S. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at $999,999,999.00,...
- This federal contract award, identified as SPE2DX15D3306|SPE2DX24FAEVF, was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of HYSINGLA ER 20 MG TABLET 60S, a pharmaceutical product, with a ceiling value of $2,382.62 and a period of performance through April 2, 2024. This delivery order contract is a firm fixed price arrangement, with no set-aside designation used....
- This federal contract award, valued at $7,177.29, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Hysingla ER 30 mg tablets, a medication used for pain management. This contract is a delivery order and has a firm fixed price pricing type, with an ultimate completion date of January 6, 2025. The contract does not have a set-aside designation, indicating open...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,070.48 firm fixed-price delivery order is for the supply of HYSINGLA ER 20 MG TABLET 60S, a prescription medication. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This federal contract award, with an ID of SPE2DB22D1106|SPE2DB25FDXY7, is a Delivery Order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,105.69, is for the delivery of HYSINGLA ER 40 MG TABLET 60S, a prescription medication. The contract has an ultimate completion date of February 7, 2025 and was awarded on February 6, 2025. It is a Firm Fixed Price contract with no...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS5EYDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,628.83 to AmerisourceBergen Drug Corp for HYSINGLA ER 40 mg tablets (60-count units) on June 2, 2025, with an ultimate completion date of June 3, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that authorizes the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, regularly fulfills delivery orders through this DLA prime vendor vehicle to supply medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. HYSINGLA ER is an extended-release opioid medication used for pain management, consistent with the company's portfolio of pain management pharmaceuticals and other specialty medications delivered under its federal contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 6/2/25 |